{"entity":{"id":"nct06015503","kind":"trial","name":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","aka":[],"tldr":"A phase 2 trial of PLB1004 in non-small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., active and no longer recruiting.","summary":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) is a phase 2 interventional study registered as NCT06015503 by Avistone Biotechnology Co., Ltd., with 139 participants enrolled, started 2023-07-21 and due to reach its primary completion in 2025-03-06. Interventions recorded: PLB1004.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06015503","url":"https://clinicaltrials.gov/study/NCT06015503"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["avistone-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06015503","phase":"2","setting":"A Phase Ⅱ,Open-label, Single-line, Multiple Cohorts, Multicenter Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","sponsor":"Avistone Biotechnology Co., Ltd.","enrolled":139,"outcomes":[]},"route":"/trials/nct06015503/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/"}]}}